Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.
about
The EGFR tyrosine kinase inhibitor tyrphostin AG-1478 causes hypomagnesemia and cardiac dysfunctionEpidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular SystemThe epidermal growth factor receptor is involved in angiotensin II but not aldosterone/salt-induced cardiac remodellingActivation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injuryModerate inappropriately high aldosterone/NaCl constellation in mice: cardiovascular effects and the role of cardiovascular epidermal growth factor receptor.Involvement of Depressive Catecholamines as Thrombosis Risk/Inflammatory Markers in Non-Smoker, Non-Obese Congestive Heart Failure, Linked to Increased Epidermal Growth Factor-Receptor (EGF-R) Production.Temporal and gefitinib-sensitive regulation of cardiac cytokine expression via chronic β-adrenergic receptor stimulation.The role of Neuregulin-1beta/ErbB signaling in the heart.Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice.Cardiac GPCR-Mediated EGFR Transactivation: Impact and Therapeutic Implications.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction.Diabetic cardiomyopathy: Role of epidermal growth factor receptor tyrosine kinase.Acute and chronic adrenergic stimulation of submandibular salivary glands. Effects on the endocrine function of epidermal growth factor in mice.ErbB receptors protect the perfused heart against injury induced by epinephrine combined with low-flow ischemia.
P2860
Q28581198-D20C5291-74F7-45FF-850B-7EA1008469BEQ33814199-971B8EB4-2AAB-4965-A3E6-170E57E30FD0Q34145896-091E0070-C4D2-4066-9412-A51BA4E0F12BQ34312113-B9F91930-A559-4DFD-8C3E-166C5F89A5A5Q34675520-0D79B3CE-77B7-46FB-8FC8-CB311A04A7CCQ35022366-8BA604F7-DF17-4D70-B5F2-409B9B5815D9Q35086445-906BB773-6496-4841-9D70-068EB8A38567Q37155921-40AF8327-88CA-4914-B946-FEEB3023D7C2Q37264435-29CDDC61-F4FB-450C-B592-57B791B20A96Q38774086-CC818340-A90A-4C77-A083-366EA1B9D6B7Q38989374-85427FF5-D35C-4AE3-BFC1-6081804E61FBQ40552347-5E8BDA7C-4343-46D9-B96A-210F496090A7Q42324509-7FBB8C2E-5991-42AB-9636-CF0C97A29466Q45920988-B3B0408B-AF71-4F63-98F1-BD32CF41EADAQ46049361-F58E7C20-C1B9-4799-A093-6B3152F0A978
P2860
Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.
@en
Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.
@nl
type
label
Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.
@en
Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.
@nl
prefLabel
Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.
@en
Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.
@nl
P2093
P2860
P1476
Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.
@en
P2093
Cordelia J Barrick
Hann-Hsiang Chao
P2860
P304
P356
10.1016/J.TAAP.2007.12.012
P577
2008-03-07T00:00:00Z